- In April 2023, B. Braun Melsungen AG announced the expansion of its non-PVC IV bag production facilities in Spain to meet the growing global demand for DEHP-free, eco-friendly infusion solutions. This strategic investment aligns with the company’s commitment to environmental sustainability and regulatory compliance, enhancing its manufacturing capacity for advanced intravenous delivery products while reinforcing its position in the European and global markets
- In March 2023, Fresenius Kabi launched a new line of multi-chamber non-PVC IV bags tailored for total parenteral nutrition (TPN) therapies across North American and European markets. These innovations support aseptic mixing at the point of care, enabling safer and more efficient administration of complex nutrient formulations. The development highlights Fresenius Kabi’s focus on advanced drug delivery technologies and patient-centric infusion systems
- In March 2023, Baxter International Inc. introduced a next-generation IV bag system featuring collapsible, non-PVC material designed to reduce waste and enhance storage efficiency. This system supports a broader sustainability initiative across Baxter’s global operations and caters to hospitals seeking safer, environmentally responsible infusion options. The product line extension aims to meet both clinical performance and environmental goals
- In February 2023, Otsuka Pharmaceutical Factory, Inc. announced a new manufacturing facility in Japan dedicated to the production of non-PVC, ready-to-fill IV bags, aiming to address rising demand in the Asia-Pacific region. The new facility integrates smart manufacturing technologies and complies with stringent safety and quality regulations, positioning Otsuka to expand its presence in rapidly growing markets such as China, India, and Southeast Asia
- In January 2023, ICU Medical, Inc. partnered with global healthcare providers to pilot an advanced non-PVC IV bag solution optimized for high-risk infusions, including chemotherapy and sensitive biologics. The pilot program focuses on improving patient safety, reducing contamination risks, and ensuring compatibility with automated compounding systems. This development underscores ICU Medical’s innovation-driven approach and its commitment to enhancing infusion safety in critical care environments
